Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Bryan J Burton, Roseann M Pruitt, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial

Blood (2024) 144 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2024-210335

Published: 2024

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II

Victoria J. Burton, Alan M. Holmes, Loredana I. Ciuclan, Alexander Robinson, Jan S. Roger, Gabor Jarai, Andrew C. Pearce, David C. Budd

Blood (2011) 118 (17): 4750–4758.

https://doi.org/10.1182/blood-2011-05-347393

Published: 2011

Journal Articles

Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function

Victoria J. Burton, Loredana I. Ciuclan, Alan M. Holmes, David M. Rodman, Christoph Walker, David C. Budd

Blood (2011) 117 (1): 333–341.

https://doi.org/10.1182/blood-2010-05-285973

Published: 2011

Includes: Supplemental data

Journal Articles

The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors

NE Kay, J Burton, D Wagner, DL Nelson

Blood (1988) 72 (2): 447–450.

https://doi.org/10.1182/blood.V72.2.447.447

Published: 1988

NARROW

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II

Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function

The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors

Email alerts

ASH Publications

American Society of Hematology

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II

Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function

The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only